Prevent Issues With Xeljanz and Other "JAK Inhibitors"

December 2019

Labeling changes will bring attention to safe use of "Janus kinase (JAK) inhibitors"...Xeljanz, Olumiant, and recently approved Rinvoq.

There's an uptick in use of these specialty meds for rheumatoid arthritis and other autoimmune diseases...since they're taken orally.

Now there's a boxed warning about an increased risk of blood clots with Xeljanz (tofacitinib). Olumiant (baricitinib) and Rinvoq (upadacitinib) also carry this warning.

Practical advice for a better career, with unlimited access to CE

Hospital Pharmacy Technician's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Practice Combat Confusing Drug Expiration Dates
New Drugs Ensure a Smooth Transition to the New Selenious Acid
Med Safety Avoid Mishaps Related to Knowledge, Action, or Memory
Insulin Be Ready to Dispense New NovoLog Generics
Medication Errors Stay Alert for Issues With Meds That Come in Starter Packs
Seizures Consider the New Nayzilam an Alternative to Diastat AcuDial
Dermatology Know What to Expect When Meds Cause Serious Skin Reactions
Contraceptives Think of New Annovera as Similar to NuvaRing
E-Cigarettes Be Aware of Strategies for Breaking the E-Cigarette Habit
Immunosuppressives Prevent Issues With Xeljanz and Other "JAK Inhibitors"

Prevent Issues With Xeljanz and Other "JAK Inhibitors"

Practical advice for a better career, with unlimited access to CE

Table of Contents